So we'll be getting started for our working lunch. And again, the purpose of this next session is to have a little bit of a report back and synthesis of the discussions that happened when the working groups had breakouts yesterday. So for each of our working groups, there's two co-chairs and one of them will be coming up and giving a presentation. We will cut them off after 15 minutes but they don't need to feel that they use the full time. And so first, we're gonna have Lauren Trepanier from the University of Wisconsin in Madison where she's a professor in the Department of Medical Sciences in School of Veterinary Medicine, presenting on behalf of both her and Dr. Wen-Hung Chung. Good afternoon. I guess I would probably get parole if I, it was in that position right now, right, except for lunch. So I just wanna summarize, hopefully, accurately, what the first working group, the smoke mic is supposed to be working but it's not. It's coming in and out, so I'm taking it out. Okay. So I wanna summarize what the, now you can't see me behind the computer. I wanna summarize what the first working group talked about yesterday, focusing on basic research gaps. And I think that our charge was similar to some of the other working groups, looking at key gaps in research knowledge, barriers to execution, maybe some out-of-the-box or missing research perspectives, what additional genetic studies are needed, what's most ready for translation, resources, and then promising areas over the next five years. So as far as key gaps, one of the first we came up with was defining the cellular processes that lead to the development of drug neo-antigens prior to MHC presentations. So trying to understand what drives drug to the MHC molecule that then it gets presented to the immune system. And we kept that purposefully broad, but in the meeting we talked about specific things that you would do to address that. The second would be characterizing how specific culprit drugs activate immune responses outside of MHC restriction. Because certainly MHC is in everything. Characterization of cofactors that drive immunogenicity, whether that's a viral co-infection or organ dysfunction that leads to high plasma concentrations or metabolic polymorphisms that are maybe less of a driver, but contribute in the absence of MHC or contribute to the presence of antigen presentation with the appropriate MHC allele. And then we talked a lot about validation of early diagnostic and prognostic markers of the first onset of clinical signs and that because these are rare infections, rare diseases, you can't really get baseline data on all patients that are treated, but the goal would be to have a strong surveillance system that you could have collection of appropriate samples at very early in clinical onset before the skin is completely soft and things you can actually get maybe due to immunohistochemistry, you can get appropriate PBMCs, perhaps urine and plasma samples, things like that, as well as DNA to try to find diagnostic and prognostic markers. And then because it's such a catastrophic disease, drug re-challenge, even though it's a gold standard for diagnosis for adverse drug reactions, it's not possible. So some reliable, confirmatory and safe in vitro challenge tests. And I think we all know what the barriers to execution are for rare diseases, especially ones that maybe have a complex phenotype is first of a critical mass of patients that are well phenotyped. We've talked about that a lot already. And then in order to get those patients and get appropriate phenotyping, you need to see them early. So you need a sentinel surveillance system that can catch patients early. And then appropriate biobank samples from early onset of disease, so not just DNA, but also potentially PBMCs and RNA later, urine samples, plasma samples, marginal biopsy samples that are gonna give you good tissue for histopathologic assessment. We talked a lot about animal models. Certainly they're lacking. There wasn't a lot of enthusiasm for jumping right in with them because we know that many of these reactions are highly HLA related and animals obviously lack HLA restriction. Yes, you can humanize animals, but since there's other things going on besides HLA, those models may not be successful and initial attempts have not been successful. And so we sort of came to the consensus that animal models could be used to test specific pathways but only after you understand the human phenotype better. And so they should be used in a more narrow range rather than just saying, we're gonna try to reproduce this whole syndrome in animals. As far as missing research perspectives, one question was, are drugs being recognized in similar ways to viral antigens? Does viral co-infection trigger these reactions? Do these reactions trigger viral recredescence? And what is it about the epitopes that are being seen? Do they mimic or cross-react with viral antigens? And then the need to look just beyond T-cells. So we know that these reactions are probably mediated by CD8 T-cells, but what are the other players? NK cells, T-regulatory cells, dendritic cells, and then looking at checkpoint blockade molecules to see if they are down-regulated or up-regulated in these patients. We also talked about chemoinformatics. So looking at drugs that have been associated with TEN and looking at their structural motifs, and certainly this has been done for other drug hypersensitivities in general, but specifically for TEN, and see if there's motifs that are in common or motifs that track particularly with certain HLA associations that might help with drug development as you go forward. And then we talked about additional genetic studies. We didn't spend a lot of time on this because there was a consensus that, yes, we need to look for more HLA associations because they're drug-specific and they're ethnicity-specific. And so get a wider toolbox for advising different populations. OXCAM type NSAIDs were high on everyone's list, Lomotrogene, of course, and then ingredients in cough medicines which have been associated with TEN, particular ocular complications, but it's not known which ingredients are actually important. And as far as most ready for translation, this is maybe a little disappointing, but really, as far as translation in the next year or so, we really felt that predictive genetic testing is really the only thing ready for translation is sort of already in translation. And that some of the other things that we talked about as far as targeting certain molecules like granulicin and things is just not ready for primetime yet. I think we all agree that we need an expanded consortium with international leadership. The United States is, sounds like we're behind the APOL partially because we don't have single-payer healthcare, that may be part of the problem, and our healthcare is very fractionated. We talked about a public-private funding model with shared responsibility from pharma, talking about not just the deaths of patients, but the death of drugs, so that there's buy-in from the drug development side and the drug safety side as well as from the physician-patient side and from the FDA side. And this infrastructure needs to provide the ability to screen and biobank patients in their early onset phase and then an international registry of patients that has standardized phenotyping, ideally based on some of these early phase biomarkers that could be developed and then molecular signatures within the biopsy itself. And these would provide the basis for adequately-powered clinical trials. So what's promising over the next five years? Investigation of differences between macular-popular rash and STS-TEN as therapeutic darkens and Lars French is already working on this, sort of, what are the triggers that take a benign course into a catastrophic course? And then biomarkers in the acute phase to facilitate diagnosis, so what are specific phenotypes? Obviously, they need histopathology, but there may be subtypes or there may be markers, I mean, histochemistry or QPCR or other things within the biopsy that would allow you to clearly define different subtypes. Using those biomarkers to then go back and look at prognosis, so who will progress? Which patients need more intensive therapy? What are negative prognostic indicators? And then, hopefully, treatment targets. So if you know what's changing in real time in that acute setting, you may know what you need to target to check that fulminant reaction that's occurring. And I think in the larger group, was talked about massive parallel sequencing of HLAs linked to medical records outcomes, so you've got this background of genotyping that's already in place as you go forward rather than trying to work backwards after the reaction occurs. And the buy-in for that is that, you know, as someone pointed out yesterday, these HLAs have relevance for many, many diseases, not just rare adverse drug outcomes, and so there should be a drive for that to happen. And then we also talked about predictive tests in addition to HLAs. So pathway analysis of GWAS data, which we're near talked about. So not just looking at the high-hit HLAs, but what's the collective impact of polymorphisms and say, you know, P450s, phase two enzymes, transporters, things that are gonna affect the amount of drug that's actually available to adduct and or associate non-covalently with an HLA. And then there's clear evidence that plasma drug concentrations actually probably are important, you know, so we're sort of going back to metabolism again. And so again, in that cute phase when you're collecting samples, looking at urine, looking at plasma, when you still may have washout from the drug, may help you understand whether there are metabolic drivers as well as HLA drivers. So I'll sit down and then open the floor for discussion. Open for questions. So there's a plethora of ideas and things to be done, but a challenge, and we've heard that several times today, is funding this. Several of us are doing drug research on drug eruptions, but have to run something else in the lab because it's just not sustainable, working on rare patient data and getting publications out within a year. And also, the Biobanking Initiative going, is not just from DNA, but you said RNA, fresh tissue, PBMCs, is a lot in it. And one question, I'm talking to Japanese, I don't know if there's any Japanese here, but yeah. They have a system from what I heard for TN and I noted that down where the pharma companies contribute from the forefront out, a part of each medication for the sickness leave or long-term sickness leave and employment of the patients and also for research center in Switzerland, I don't know how it's here, but when you buy a MacBook Air, you pay when you buy already for the destruction and recuperation of bits of it. And then I was wondering when you were discussing from a FDA perspective, for you, it's also an issue having good quality data to be able to make the label good and that's gonna come with financing. If there's no way to try and get the companies to put a little center to off every package of pills going into that, it's in their interest, it's in the interest of everyone from the front. Yeah, we had talked about that a fair amount about public-private cooperation and so the various regulatory agency, the various research funding agencies of the various countries and their regulatory agencies but also pharma, it seems like an obvious source of funds and I'm not sure the logistics of making that happen in our political climate, but it seems like that would have to be part of the puzzle. Because as pity they come running when they end phase one or phase two have a severe adverse eruption and then they wanna invest lots and really have results in a month. That's not the way it's gonna work. So Cynthia, were you? Yeah, I was just gonna ask if Taiwan could, because they have the Taiwan Relief, Drug Relief Foundation, can you tell us a little bit more how do the drug companies contribute into that? Yeah, but virtually most of the funding are for a patient, not for research. So far, only not so many fundings that they can do for research purpose. So, but we did raise some funding for the drug company over every year, so we get more than three million or four million US dollar per year. But I think in the future we can push the government to do some research from the foundation. Linear. So we discussed this and funding is crucial here for not only for initiation, but also for maintaining any resources that you have as well as undertaking studies on the samples that you have with the new technologies which are coming through. And as you know, all those new technologies increase the cost of each experiment that you do. But the majority of drugs that actually cause problems are generic, off-patent. And so therefore this is not a problem just for farmer, it's actually a problem for healthcare, it's a problem for regulators. It's probably unlikely that one funding agency can fund all of this. And so therefore it is probably important to have a global consortium to be able to do this. So NIH working for example in the UK with Wellcome Trust, MRC with the Japanese funding agencies, et cetera. And that way that may be the only way to be able to lead some kind of sustainable funding in an area like this. Obviously there may be some small areas which may be focused and so on which could be funded by NIH, MRC, Wellcome Trust, et cetera. But here in terms of a global perspective that one really needs to think about how one can develop, get the funding in, but also maintain that resource that is developed from that. Okay. So maybe, come as no surprise that people recognize the need for funding and that you're going to tell us that we should fund it. I think it would be very helpful to spend our 15 minutes really kind of focusing on what is it. And what are the high priority studies? What are the key needs? What are the things that are obstacles as Lauren kind of laid out for us, I think very nicely, but in terms of a consensus of the group, where do you see the real pressure points where we could make some real progress? Neal. Okay. Well, since I was recognized by the chair before you said that, I just want to make a comment. I think puts it in some perspective and the disclaimer is this will never happen here. In Sweden, there's no fault insurance that the manufacturers pay into and in Japan too sort of that sort of description. In other words, if a patient has suffered harm from a drug or a vaccine, there's a central fund of money to help recognize that. And what it does is it recognizes the physician who prescribed the drug can still talk to the patient. They don't have to run home and hide under the bed. They can keep their relationship with the patient going. They can initiate the patient's participation in that fund to be recipient and if adjudicated, it's usually settled in about six months guaranteed.  So what it does is it keeps the patient physician relationship there, collects wonderful data, funded by the industry, no fault anywhere in the world, you can't go sue somewhere else. You can see the obstacles here. It's actually, it's intensely sensible. It's a good use of money and extra money could be used for research. But if there's any lawyers watching, you're probably already calling your congressman saying don't ever let this happen. And because that's who would end up losing in the end is the lawyers. So thank you, Neil, but I think I'm gonna come back to Terry's point and bring the question and maybe I'll start with Wenhong by just by asking you to chime in. As you think about the items that came up, if you wanted to pick your top one, I know that's always a pressure thing to do from the discussion yesterday. What would you lead with? I think most important resource issue we should do is to get a good sample by banking over the sample, especially from the very early stage. So it's very difficult because most of the sample we, now we call it is expected to call the patient back to get the problem. But if you were trying to find out the biomarker, the circular target, we need some very early samples. It's very, very difficult for most of the researcher to do that. So I think we need to have a core whole and the perspective and the kind of the international consulting to collect the more sample size. I think it's more, it sure has many, many other people in risk of doing that. I think there's some infrastructure here that you could just go forward and say, all right, this is, these are the types of biomarkers that have promised for development. Plasma proteomics, just doing IHC, QPCR on biopsy samples, looking at PBMC, cytotoxicity, things like that. These are the samples that we would need and focus funding on study those kind of studies that are gonna develop a bank of biomarkers. The goal would be to have therapeutic targets because you're never gonna eliminate the disease completely, but if you have a good therapeutic target, then you could at least decrease morbidity and mortality. Sir, I think it would be easier if we do it in a clinical trial of different interventions, like because right now we do not have exactly the efficacy data of various treatment options, IVHG, cyclosporine, corticosterone, and if you run the trial in Taiwan and then in that trial, you can get all the samples because when we enroll the patient into the clinical trial interventions, this is, we need all the samples from them, right? And we monitor, we can monitor them through until the final sequelae after the Steven Tens was treatment, either patient die or they have complications or survive. And in that case, we will be easier to get, I mean, the biomarkers if there is one. So I think a large clinical trial to test the efficacy of various options may be good. Thank you, Mark. Yeah, I just carry on with that. I think a clinical trial is good, but one of the things that struck me about the presentations yesterday is that the identification of the disease is probably way too late in terms of really looking at effective interventions. And this is not specifically related to the basic science group, but I think in terms of takeaways for today, this would relate to some of the things that we talked about in group three about surveillance and identifying early markers of individuals that are in an early stage of Steven's Johnson Tens where, and if we could in fact accomplish that, then that would I think support a more effective enrollment into a clinical, into an intervention trial. Yeah, I was actually just thinking the same thing, and I don't know if some of the people around the room who are really involved in this can talk about what you see as challenges of getting earlier onset identification of cases. Mark. I wanted to follow up on actually what Mark had talked about yesterday, that the numbers are too small to actually get the cases of interest from a clinical trial, and also you get them too late. So by the time you get them, the thunderstorm has already happened. So you're just getting the footprint of what already has happened, which is a lot of different injury markers. They're not necessarily the harbingers, but what you can have, what was mentioned yesterday is the positive, the patients who have the positive marker, for example, carbamazepine in that marker, 1502, the patients who don't get the reaction. And so you can look for markers of people who don't get a reaction and ask what in that mix of, you know, from a biological perspective, might explain the protection effect. You know, if you had an animal model, you could study, for SJS, you could study it serially on a timeline from initiation of exposure and then every step of the way. But since you don't have that, which would then be ideal, then you could kind of find the early marker, the harbinger. But what you could do is look at individuals at a later point in the clinical trial who don't get a reaction or will get a minor skin reaction who have some adaptation. Lars? So if I had to choose from all, I think it's pretty clear that it's immunologically driven. It's pretty clear also that some of the patients who have a defined HLA, which is a risk factor, some of them, despite that, won't develop the disease. So a co-factor is needed. And I think research for that co-factor would be really important. If we could target that, we would have a lower incidence and we'd probably maybe be able to turn it off. HIV is a co-factor, and ampicillin EBV is a co-factor. So there's some evidence. It may be a pathogen. It may be signaling through innate pathways. And I think that's really something that's been under-researched and has to be looked at. And do you think the appropriate time to look at that is as the early surveillance and when the reaction's ramping up or before the patient is treated? Yeah, I think we have to really get as much samples as we can. Early samples, PBMC and skin samples, and then run them with the techniques, beautiful techniques we have to try and get leads. But there's quite some in vitro stuff you can do too, with hypothesis-driven and not non-biased, really, hypothesis-driven on PBMCs or on mixtures of PBMCs and keratinocytes. And some of this you may be able to do by having the patients, knowing the patients and going back to them six months afterwards and getting the PBMCs and getting keratinocytes from hair follicles or from biopsy, putting them in culture and working with this. We know that we can do the lymphocyte transformation tests a few months after and that works and those patients will survive. So it's not only the acute phase, it's getting material also later on in vitro. I think regardless of fundamental infrastructure is needed and the capacity building is going to be key. And I think what maybe differentiates this from other initiatives is the need for broad international collaboration to get the cases. And I would be interested from Terry and others in terms of within the NIH framework and FDA framework and maybe broad collaboration across not just the NIH, but other FDA, other regulatory agencies internationally given the international presence here and the need for international collaborations are there ways to actually facilitate that or make that happen? Well, sure, I mean NIH does, we probably fund more research internationally than any other funding body funds outside of their country. So there are many good examples of collaborative projects that we've done as Munir mentioned with the Welcome Trust and the MRC and a whole variety of other agencies. I think that the bigger question may be how would one sustain such an effort because one of the challenges in the area of drug safety is that it never goes away. And once you get started down that road which is an important road to start down, it's not clear that the research agencies can sustain that effort. So are there ways then to work with other agencies? And we've talked about a few of them here today in terms of the US, the CDC, our Centers for Disease Control, our Agency for Research, Health and Quality. And those may be agencies that could pick up some of these efforts down the road. But I think again, first rather than perhaps sort of figuring out who's gonna fund this and how we make it funded, we need to define what the what is. So if an international collaboration is something that sounds like everybody is enthusiastic about, what are the key things this international collaboration would do and how is it different from those that already exist? Biobanking is sort of the fundamental sort of first step is getting samples that aren't currently being collected which includes PBMCs which is not and tissue and so there's been a lot of work on getting DNA and DNA banks but I think we need to broaden our repertoire of samples that are being collected. So DNA, RNA, serum, plasma, cells. Okay, so Moonier and then Lars. So we've heard that so many people have biobanks and collections already. I guess the question that you asked Terry is what is it, what's different? I think scale and upscale what we do and tremendously increase the scale of what we do by this global collaboration. That's number one in terms of difference. I think in terms of key factors that we need to look at, we need to look at the predictive biomarkers, the diagnostic and prognostic biomarkers and key for that particularly for the latter two will be identifying patients early. Now that is a challenge and you'll have lots of false positives but getting those patients identified earlier as was stated earlier today and we discussed that extensively yesterday will allow you to be able to identify those kind of diagnostic biomarkers which allows them to be able to undertake stratified trials in smaller numbers of patients which at the moment you can't do because it's such a rare disease so undertaking trial in this area is going to be immensely difficult. So having those kind of early markers which allow you to be able to stratify undertake kind of Bayesian type trials will be the only way to be able to then really test some of the therapeutic interventions. Lars. I just wanted to add on to these two comments that biobanking can't go in my opinion without a registry and that's as we discussed before with well phenotyped cases so that you can have the clinical data to it and then one big element if we had to have an alliance together is talk the same language. So harmonization for the clinical characteristics we're bringing in our registry so that we can really exchange well. Yeah and I think part of that is also thinking about expanding to areas with high numbers of cases that don't have the infrastructure in place yet and so sort of both retrospectively putting together groups that are working and then thinking about how to best move forward into new areas as well. Steve and then we're gonna move on to the next group. I think together with the early identification with patients in collection of biomedical samples whether it's plasma or cellular materials there needs to be centers that can receive them and work on different parts or touch different parts of the elephant and so Lauren and her summary of what their group did identified the various steps between drug administration, drug bioactivation, processing of the neoantigens all the way through to the immune response probably you're looking at four or five specialized centers that can work on each of the components that might be involved but there also needs to be a way of sending peripheral blood mononuclear cells from Kansas City, Missouri to Switzerland or wherever that aspect of the big picture is going to be worked upon. And so I think there's a lot of elements toward making this happen that would have to be worked out as well. Very good point, thank you. So we're gonna turn over now to the report back from working group two. I don't know if Howard or Srikabeth is going to the podium.


Earlier in the week, there had been forecasts for the game ranging from single digits to below zero. So you would assume that if it's 29 degrees, 23 degrees, I don't think weather plays that much of a factor. A lot of people would have said, well, if it was single digits or zero, it would have affected the older quarterback. And I even brought it up earlier in the week, how it affected Brett Farve. It didn't affect Eli Manning. But Tom Brady is almost robotic. I don't know. Brett Farve was a great player. I don't know if he was ever a great athlete or an unbelievable shape, should I say, like Tom Brady is. I don't think that the cold weather would have derailed Brady at all. I think it might have hurt Kansas City's explosive offense, because there's certain things you just can't do. I think that with this weather, guys, I know the Patriots are playing the underdog angle. There's a first game that they've been an underdog in 53 games, but talk me off the Chiefs, Don. Talk me off the Chiefs in this one. I can't. I really can't. You're talking about the weather. Well, how is it going to be any different than it was last week? There was snow on the field at Arrowhead when they played the Colts, right? So the weather can't be a man and do it. So it might even be better. So Michael, be a man and do it right now. Do it. I'll do it right now. Because guess who I like? The Pats. Do it right now. You see what he's doing, Don? Do it right now, because I love the Patriots, baby. He's making an absolute mockery. I love the Patriots. I like the Patriots, too. So if I pick that. No, but I said it first. Okay. You didn't even give your indication. I'm telling you right now, I'm leaning Pats. So if you go Chiefs, that's it. Lock it. Load it. I don't think, honestly, in a show that is going to be majority talking about these two games that we can't show our hand, Michael, we have to. No, no, it's fine with me, but he's being an imp. He's being that bad guy, because the only way he can win is to sit there and hope that I implode over the last three games and that he gets a tie. And frankly, that sickens me and it cheapens the competition. You started it by saying, talk you out of the Chiefs.  Yeah, but you know what? Maybe R.J. Bell talks me out of it. I haven't made a pick yet. Yeah. Yeah, of course we do. We would have had him yesterday, but just the 16 minutes just wasn't enough. You should have squished him in. I guess we got to show our hand. R.J. Bell on a 16 minute show would have done 40 seconds would have been tremendous. I believe I'd be the Los Angeles Chargers beat themselves in that game. They were intimidated walking into that building. Now Kansas City's host in the game. You've seen Mahomes answer every single question that has to be. Don, you have been so well on the Patriots this week. I have never seen you so wrong. You're right about everything.  Some would say Savant. You've not wanted to give the Patriots credit all week. They dominated. That wasn't just the Chargers beating themselves. That was a brilliantly coached and executed football game. No, absolutely. But the game, you can't ignore the fact that the game is in home at home. And again, I'm reading Bob Globber's book and I know he promoted it every two seconds, but it's such a good book. You should read it about when the Giants lost to the Bears in 85. They believed they were just as good a team and they dedicated themselves after that game. So we have to get home field advantage. We cannot play on the road and New England is different. They're three and five on the road this year. History shows that if they're going to be beaten, it's going to be on the road. This Kansas City team has been one of, if not the best teams all year. New England has not. All right. So I was wrong last week. All right. The Chargers did not come up big and give the Patriots credit, but I still believe that there are cracks in this armor. I still believe that the Patriots can be had. And I think the Kansas City Chiefs have all of the ability and the location of the game to get it done this Sunday. You know what? I look at it and I go, I don't know if the Patriots could stop Patrick Mahomes. And I believe that Kansas City could slow down New England and New England really won a game. And I'm not taking anything away from New England, but I thought that Anthony Lin got coached under the table. Just awful. Didn't make any adjustments. Andy Reid might not win the big game quote unquote. He's always been a pretty good coach. He has a pretty good staff. I think that they would make some adjustments. If anything, they become a little bit conservative with a lead, but they would have changed things up. They would have gone away from the seven defensive backs that the LA Chargers had. So I just don't think the Patriots are the best Patriots. And you know, I've always been a Patriot fan in terms of picking them, but you cannot ignore that they are three and five on the road. I think Troy Wingo had a stat today that he tweeted out. Don't know if you guys saw this, that only two teams have made the Super Bowl with an under 500 record on the road. So they're three and five. You can't ignore that. And also they're one and four in their last five playoff games on the road. The first two playoff games that this group ever played on the road, Tom Brady, they won those two. So people keep giving you the three and four number. No, no, no, they're one and four. So since 2007, one and four playing away from Foxborough. That's significant. And here's an amazing thing. Do you realize why this game is being played in Kansas City? The Miami miracle. If they win that game against the Dolphins, this game is in Foxborough. That wacky game coached by Adam Gase, that was the difference between the game being in Foxborough and the Patriots probably being favorites and being in Arrowhead and being underdogs by three and a half points. Rob Gronkowski wasn't the last line of defense trying to save the Patriots from losing that game.  But that one is the one they didn't know. For the most part of this season, let's not change our feelings here. The Chiefs were better than the Patriots. Almost all year long, 80% of the time, we all consider the Chiefs to be significantly better, I would say, than the Patriots. They would not be playing this game at home, so the Patriots would have had a better record. It was a close game, right? Yeah, 45-41. Let's focus on the games the Patriots did win on the road. They won three games on the road, Bears, Bills, Jets. So the only good team that they beat on the road was Chicago. That was a significant win, but Chicago didn't have the offense that Kansas City is going to bring to the table. So three and five and really only one quality win on the road in Chicago. Otherwise, the Bills and the Jets were the only other two wins away from New England. That's significant.  They might have advantages in Foxborough that we have no idea what they are. But there's an advantage to playing at home. And if you've ever been to Arrowhead Stadium, and I've been talking to a couple of people this week that have covered games there, it is one of the great home field advantages in all of sports. It's definitely loud. Before Quest Field was built in Seattle, Arrowhead Stadium had the loudest decibel of any place to play football. And up until last week, they had not won a playoff game there since 1994. But they had not had a great team. They still had playoff games there. But not that many. They usually didn't win their division, so then they would play on the road. No, well, but they had a handful there. They didn't win any. Okay, but they weren't that good. Now they have Patrick Holmes. As Trey Wingo says, future Hall of Famer Patrick Holmes. I hear you, but they had some decent teams. Some of those Schottenheimer there, they had good teams that had home field and they'd lose. That was their problem is that they'd go up against an Indianapolis team. Indianapolis would be 10 and 6. The Chiefs would be, you know, 14 and 2, 13 and 3. And they'd blow the game. But this seems to be a different Chief team for sure. And I don't think, I'd have to double check. I think this is the first time they're actually hosting a championship game. They never get to the championship. They haven't been to the Super Bowl since Super Bowl 4. We talk about the Jets. The Chiefs are much better. I agree. I agree with everything you're saying. I mean, sometimes, you know, those, those awful records could be tossed away because this team seems to be beyond that. Now let's move to the other game very quickly. Another three and a half point spread. The Rams are three and a half point underdogs to the Saints and the Saints beat the Rams earlier in the year. But remember one thing, they did not have a key to leap at that point. So now they do. He's back from injury. And I think that makes a big difference in covering some of the weapons that the Saints have at wide receiver. And I think that will make a huge difference. There's another stat that's really interesting. Over the first, and I'm just rounding this off over the first like 10 or 11 games of the season, the Saints are averaging an outrageous number of points per game. And they have completely almost lost two touchdowns a game in the last six games. It's disappeared. Like now they average 20 points, which is not bad, but it's not the explosive offense that scares everybody. So if they only scored 20, and I was reading today somewhere that some people think that Drew Brees' shoulder might not be that great because he's not trying any passes downfield. Remember, two passes were woefully under thrown of wide receivers that were wide open last week. So if they scored 20, does anybody think that the Rams, the Saints offense, is going to hold the Rams to 20? I don't think so. Again, talk me off the Rams, Don. Just because I think the Saints defense is better than any defense they've ever had in their history. Yeah. I mean, so they scored 20 points in the last game, but they were able to hold Philadelphia down. They came up with the stops necessary. Philadelphia had those two scores early and then were shut down pretty much the rest of the way. So I agree with you. Something scary. They got out of their mojo with those three straight road games late in the year where they averaged less than 17 points, but they never seem to get the mojo back. But this defense can play. It was the Cowboys game. They scored 10. Then they put up 28 against the Bucks and 12 against the Panthers. But one thing you have to take out the game with Drew Brees didn't play. That's, that's the last. So take the 14 against the Panthers. Right. Take that. That's another one. So even when you take that out, it's still 20 points a game in the last five or six games. And Andrew, remember they only arrived and Andrew, you remember they only scored 48 against you guys. So wow. Really? That's what you have to do to the guy? And you know what, while I'm doing that because I'm not a fraud, they put up a mere 43 against the Reds again. So I'm there with you. But Andrew's team is a good team. It's a very good point that in fact, they just lost last week. I heard after Alson Jeffrey dropped a routine pass that Jack Gunling could have caught and taken advantage of Bill Belichick. I mean, he's lived for these championship games and you wonder, does he get nervous? And here's this exchange with a reporter about if he does in fact get nervous for these games. Yeah, every week. Yeah, every week. They all count as league. Just let me know the next game that doesn't matter. So I can take that into account. So just let me know the ones that don't matter. But I'll make sure I don't get excited for those.


This is going to be a short video. Someone sent me this link to an article on natural news. Natural news is a hive of anti-science, anti-vaccine, and pro anything demonstrated not to work, also called alternative medicine. But it's also given me a classic example of bad science blogging. The author here, Ethan Huff, is attempting to make the flu vaccine sound like it's really ineffective. He focuses on the official CDC statistics, which show the current seasonal vaccine to be about 60% effective in preventing influenza. He links that to the current serious outbreak across the Northern U.S., with 24 states at high activity, and another 16 at moderate activity. That's a big deal. But it's when Ethan here attempts to outsmart the evil corporate governmental pressers at the CDC that the comedy really begins. Here, he implies that the CDC is attempting to confuse you or overstate the effectiveness by calling it 60%. His reasoning, only 2.7 in 100 adults get the flu every year, and that number drops to 1.2 in 100 among those who are vaccinated. Thus, he concludes the vaccine is only 1.5% effective, not 60%. I can only face palm. The reduction in absolute incidence, that is the number of people who get sick, does indeed decrease by 1.5 percentage points. But that is a 60% reduction in disease when compared to the unvaccinated population. This is a common mistake when people talk about percentages. A percentage point is unit change per 100 units, while a percentage change is the amount of change divided by the total. Why does it matter? Well, in actual disease prevented for one, a vaccination that was 1.5% effective would reduce the absolute rate from 2.7 to 2.66, which would save about 140,000 people from several days of misery. While the actual value, a reduction of 60% or 1.5 percentage points, if you prefer, would actually prevent over 4.5 million cases of wishing you were dead. Given that influenza infection generally increases mortality by about 1 in 10,000, that would translate to about 500 people who will see 2014 that would not have without vaccination. So, how does the regular audience of natural news respond to Ethan's rather obvious mistake? Exactly like you would think. Even after the error is pointed out by an astute reader, the rest of the group are so eager to pile on the bandwagon that they aren't prepared to stop and fact check the glaringly obvious mistake. Who, after all, thinks that any medical condition that was less than 2% effective would still be in use? Why, there aren't any practices like that. Well, outside the world of alternative medicine. Stay safe and healthy out there, and thanks for watching.


Hello and welcome to the Grand Line Review, your source for everything one piece, and today we have a review of chapter 971, Sentenced to Boil. And we are sadly officially here. The tragedy of the Odin flashback is in full swing, however in classic Otis style, meaning that this character is not going down without being solidly ingrained into our minds for the rest of our lives via his actions, as is the case with most flashback figures. And it's really interesting actually because this chapter once again slows down the overall pace of the Odin flashback, in order to focus in great detail upon this event, which isn't even concluded this week actually, but that is the case for very good reason. In my mind, the way this chapter is put together very much mirrors Odin's bargain with Kaido to survive in the pot for an hour, which would surely be the most excruciating hour of his life, and in fact there's a point in the chapter where it becomes apparent that only four minutes have actually passed, and I had this jolting thought of, are you serious? It feels like so much more time has gone by, but in reality it's been practically nothing. So I do quite like it because by extending this scene, not only is it granting Odin the emotional resonance that an execution needs, but it's also making us, or at the very least me, actively feeling Odin's torture. And I feel like the choice not to conclude the execution this week was very cold for, because now we as readers have to live with this idea for another whole week, rather than blasting through a chapter that simply tells us that this execution is going to take an hour and having us, you know, not really feel that. But instead, to us, we'll be living with this event for like two weeks as a result. And this is probably one of the rare instances in the series that I would say is at peak effect when reading the weekly manga, rather than going through it comparatively quickly in volume format. And slowing things down just allows Odin to explore so much more in terms of art, because there are actually a lot of small panels here and there that usually would not make their way into a standard one piece chapter, because you know they have to be so chock full of story and progression. However chapter 971 takes a lot of space to show random shots of the flames or the boiling oil or various close-ups of the impact that this is having on Odin's body. And I also quite liked that because we as readers needed to truly understand just how gigantic of a feat Odin's actions are. And for that we also needed an example of how this oil would affect a normal human. So one very, very poor unfortunate individual, you know just so happened to whoops slip in and pretty much instantly die. And look I don't feel bad for him because chances are he was a bit of a prick anyway. I mean he does look like the Orachi loving slime ball type, but as a result when Odin hops in the pot and lets out that guttural scream, well to be honest this is probably one of the most painful things I have ever read in this series. Seeing that panel gave my skin a phantom burning sensation, where I was subconsciously picturing myself being hit all over by hot oil, like what would happen from time to time when cooking. So yeah man all I have left to say about that particular panel is ouch. And with those feelings in mind, my favourite panel I guess it's more of a spread, is Odin lifting all of his vassals because this is just classic one piece, a brilliant left field heroic manoeuvre from a character who was larger than life. But this panel is fantastic because of all of the expressions being made by the vassals, which range from the sort of shock you can see painted all over Kaomatsu, to the deep concern on Nekomomushi, all the way to the incredibly pained Kinamon, who seems to be one step ahead of everyone else in terms of understanding exactly what Odin plans on doing here. And it's heartbreaking it really is. And in this moment I empathise with Kinamon more than I ever have in the history of this series, which is pretty impressive, because this guy goes quite a way back now, all the way to the days of punk hazard, but for the most part he's always been such a joke, and now he is almost the emotional core of Wano in general. But the other key feature of the chapter was the revelation of the interaction between Odin and Orochi that resulted in him acting like a naked fool for five years. Now I was pretty heavily critical about that particular chapter because the decision not to show that interaction there left everything feeling very jarring and annoying. However I did tell myself that this was because Oda was planning to use that information at a much more dramatically potent point to really hammer something home. And it would appear that that point of choice is here. And honestly I'm not sure how to feel about it.  And yes, it does give Odin's actions a much more reasonable motivation because when faced with the lives of 100 men, women and children, I highly doubt that any of us would make an aggressive choice so lightly. Now with that said, I'm still not entirely sold on how this went down at all. I don't think that Oda has effectively portrayed this as a Sophie's choice, whereby Odin had to go one way or the other. Because I still think that he could have just struck down Kaido right then and there, and from there taking down Orochi and the Bari Bari No Mi user, look it would have been tricky but achievable, very achievable. Well if he was super serious about wanting to save the lives of each of these 100 people, then gather his forces and infiltrate the castle at night, assassinate Orochi, take down Kaido, and or discreetly free everyone. And I mean I get what Oda was trying to do, and it's to highlight how much of an incredible figure Odin is, willing to sacrifice every shred of his honor for a handful of people. And in fact honestly, I think he would have done the same for just one person. That's just the kind of guy that Odin is. It just doesn't make a great amount of sense because he has so many more options available to him. And the real kicker is that in this chapter, Orochi's goal is effectively revealed, which is nothing more than to drive Wano into pure ruin. And we'll get back to this in a second because I actually do find Orochi much more interesting as a result of this chapter. However I do once again ask myself, what was Odin's endgame here? Over time, Orochi was only going to destroy more and more of Wano as we've seen, plunging the country into the state that we now have in the modern day. Like, there are no two ways about it. Orochi needs to be removed from power ASAP, and Kaido needs to be completely expelled from these lands, if not life itself. No amount of naked dancing is going to save the rest of the Wano country folk from a social, economic, and political erosion being conducted here. And Odin despite having an undeniable Luffy-like quality about him, is certainly intelligent enough to identify that. Although to be fair, maybe that's his issue. Odin is too smart and overthinking things. Meanwhile, if Luffy was put into a situation like this, his only thought would be, so to fix everything I just need to beat you up, right? And then he would proceed to do so. So yeah, in the end I'm not quite satisfied with how this part of the flashback ended up playing out. I was just hoping for a much more solid revelation with this, but whatever, let's move on. Going back to Orochi briefly, he actually, oddly enough, becomes somewhat identifiable. Maybe identifiable is not the right word, but I'm not changing it. But because the story of how the Kurozumi clan were persecuted is actually one that is quite horrifying and very much speaks to the darkness that was present on Wano prior to all of this Orochi-Kaito business, because you know, assumedly the names that we would consider the quote unquote good guys like the Kozuki clan or the Shimotsuki clan would have had a hand in this. And Odin realizes this as well because he has this look of proper empathetic shock, whilst Orochi is explaining what happened to the Kurozumi clan. But in general, I do quite like this explanation. As well as the idea that Wano has fallen into this state, not because of any outside faction like the Beast Pirates coming in and just ruining everything, but because the country effectively did this to itself. But with that said, I can't help it feel like there's more to this story than we've seen, just because this massacre of human life seems so inconsistent with everything that we know of prominent Wano figures such as Tsukiyaki or Yasu. So there may very well be a much more nuanced explanation for what happened to the Kurozumi clan. However, I kind of hope that's not the case because taking Orochi's words in here makes Wano an infinitely more complicated location within the One Piece world and I love that. I really enjoy the idea that saving this island is all of a sudden going to be far more difficult than just beating one of the four emperors, because Wano needs to heal and rebuild itself in every aspect of its society and its leadership may even need to own up to what they did to the Kurozumi clan and recognize its own past sins before moving forward. So there's a lot to play with here and while it certainly does not make Orochi a character one can empathize or sympathize with in the slightest, I do at the very least understand his goal and I'm glad that he isn't a completely flat antagonist. Speaking of flat though, take a look at Dem Kaido legs. It's kind of like a set of chopsticks. In fact, he actually reminds me quite a lot of Duval in this panel. You know that completely stacked up a body physique with legs that look like they would snap in response to a light breeze? In all seriousness though, I do find it interesting that Kaido continues to have a comparatively minor role in this flashback. He is very much a side character and once again I think that's for the best. Bringing too much of him into this may risk losing the focus on Buono and its people, although I do really like seeing the prior incarnation of his design though. It reminds me that Kaido was not always the invincible powerhouse that he is today. This man, dragon, creature thing probably had to work and work and work to get to the level he is and yes, he may have some sort of gifted invincibility that stops people from killing him but when you think about it, Kaido is probably known as one of the most notorious losers in all of One Piece. I mean, he's been captured and defeated roughly a billion times so this guy was certainly not the epitome of power throughout his whole life and certainly not at this stage in particular. And one more thing I will say about Chapter 971 is that I think any traitor theories within Odin's vassals become a lot more difficult to swallow after this week. Like each and every one of these guys was on the verge of being boiled to death so unless this is an incredible play from one of them, I just don't see it happening anymore. For one of the vassals to continue to betray Odin after this action would be incredibly heartbreaking and he would instantly become one of the most hated characters within the entirety of One Piece. Although to be fair, Odin could very much go to that territory. At the moment though, I would prefer to think that the traitor comes from outside of the vassals although sadly that doesn't leave us with a lot of options either. You know, we're looking at Toki, Hiyori, Momonosuke, or one of their servants like people and really there's no way it could be Momonosuke and I highly doubt it would be Toki either.  Whatever the case, it would seem that within this chapter the hour of legends has begun because at this point I think it's pretty clear that this event is what that was referring to because the one hour time frame is very specific and rather sadly I think that Odin will probably be dead by the end of next chapter because 971 did a lot of work to really draw out this experience and allow us to feel Odin's struggle so with that freshly in mind the next chapter should be free to cap off the life of this incredibly profound figure to close out this flashback and that pretty much does it for chapter 971. If you enjoyed this video and the content this channel produced in general then please do consider donating to the Grand Line Review Patreon because the support of all of your amazing people is what continues to make this channel possible and if you'd like to see more videos like this but applied to other anime manga series then please do feel free to check out my second channel New World Review for all of your wider needs and if you'd like to join the fun at any time then please do head over to my discord server where a wide array of shenanigans takes place on a daily basis and finally please do comment with your thoughts on the chapter. This has been the Grand Line Review and I'll see you next time.


So, the image is formed at 6 centimeter, clear? Point number one. Now, height of the image upon height of the object equal to minus v y u minus 6 by negative 10 is equals to magnification. So, the image is diminished in nature, clear? Sure, it is virtual and erect. So, where is the image formed? Magnification, nature of the image all done. We are happy in this world. Next question.


What's the word y'all we had a couple game tools today and I always say there are three games in the seven games series that are super important Obviously game seven is the most important game five is super important But game two people don't be thinking but game two is super important to because an NBA history If your team goes down oh two in a series They are losing this series 92% of the time So we had three different teams trying to prevent themselves from going down oh two and only one did we saw the 76ers beat up The Toronto Raptors are gonna talk about that obviously. I'm recording this during the Warriors Nuggets game. Yoko's got ejected It's over.  It's disgusting We don't talk about the game Even though it ain't completely over I'll talk about the things that I did see but the game that pissed me off the most and The best game of the day so I can't even be pissed because we got good basketball from the Utah in Dallas game Oh my god listen. Oh, I did the discourse on Twitter and everything Blows my mind the Utah Jazz should be ashamed of myself The fact that I'm recording this video right now is actually somewhat of a of a miracle I guess a lot of y'all know that I had a daughter a couple days ago three days go to be exact I appreciate all the well wishes that y'all said my family way and you know You have babies you send them in to get testing just to make sure everything is working the way it does and We send them for testing and they were like we need you to stay overnight And I was in the hospital room watching these games and my wife looked me in my eyes and Shoot home go record your video and come back Can I get some W's for my fiance for understanding the grind does not stop and my baby's okay if it was something serious Obviously, I wouldn't do it's nothing serious. She's okay, but I'm here You know I'm saying and I'm recording this send over to the editor editor and I'm shooting back to the hospital That's like five minutes away So I'm not even that far if the case something does go nothing is going wrong Okay, let's talk about these games y'all because Dallas Prevented their sales from going down O2 in a series where look at Don just has a play The Utah Jazz should be a shame of themselves from losing this game and they were this close to losing game number one So maybe it's a blessing that they're not down O2 right now This team pisses me off so much because if you remember before the season started I had them like I think I made a video that was five potential dark courses for the NBA finals And one of my teams the Utah Jazz and that's not looking great right now any Dribble penetration is going to destroy the Utah Jazz and the whole Conversation revolving around this is surrounding Rudy Gobert Rudy Gobert is a three-time defensive player Do you he just finished 30 defensive player shout out to Marcus smart for winning it for the guards for the little man out there? We love that And he finished third again and in today's game on the surface First surface level you see Maxi Kleber hitting eight of eleven threes and you would say oh Man Rudy Gobert three ten offensive player the year for what and I am here to say Though he was not perfect defensively this game because it's hard to be perfect on anything That's not his fault. I'm making the same argument and Rudy Gobert's favorite The same thing I happened to do last year when Terence Mann went off for 40 I'm doing it again because y'all are not watching these games, right? If you think that Rudy Gobert is he is the main reason for this team not being successful today Let's be honest one of the reasons why this team is not successful today or it might get eliminated is round because when Luca Come back in three days. Oh, um, you think that the dribble penetration from Jalen Jalen Brunson was bad Wait to look away to seven seven wake up the the main culprits of all of this is a the front office I don't know how you can see what your team did how they went out last year and look at all the holes Did you have in a perimeter defense to be like, you know what? We're gonna we gonna bring in Rudy gang Or you you see that you're still having these problems at the trade that line and what you do We're gonna bring in a kill Alexander Walker who are not even gonna play for us So they are my main blamer number two is Quinn Quinn Snyder, bro He's been a very good regular season coach for the entire defense time in Utah But something has to check like you have to make some changes down the stretch when you see that this scheme that you're Playing defensively is not working that you gotta change it you guys to change it in three Well, everybody else is on a perimeter though and then then Rudy go bear this fourth because again He's not perfect the perimeter defense was God awful and I gotta give a lot of love to to Jalen Brunson I made a tweet that I'm excited to see what type of bag He gets this offseason because he was already having a very good season because he's a guy that you could see He can play alongside Luke and be successful But you have the games where Luke is not playing and he can do this 41 points eight rebounds five assists Not a single turnover for one of the lead ball handlers on this game in this game Amazing work from Jalen Brunson He got passes defender at will and what did that lead to open three point shots because the way the Utah Jazz Play defense is Rudy We need you to play the paint no matter what because we'll take our chances on three because two the chances of that Layup going in is very high compared to the three point shot So that's just this is why you get a maxi cleaver game Or this is why you get a Terence man game because Rudy has the assignment to cover the ass of everybody That's getting blown bad on the defensive side of the ball So shout out to Jalen Brunson shout out to Spencer dimwitty and shout out to maxi cleaver because he had to hit the shots Getting open looks at something you get in the NBA, but you have to be able to hit him and he did that man This is so frustrating bro. This is so very frustrating. You know what I might get demonetized So all I asked for you is to leave a like on the video the NBA It's not gonna like that I'm showing their footage But I want to show you a few plays from this game and a lot of these are maxi cleaver stories right in this play There is no really go better to sound white side But so this is just shows you this is a scheme thing and it's not just oh it's really go bear who's sitting on a Salad probably poutin first of all before I even get into this We were talking about after game number one that they got to find really go bear more because he had like one shot It's him for something I take that back love really go bear love really go bear Don't give him the ball no more just don't are we get we on the greens on that okay? Cool, so you got Jalen Brunson with the ball the only guy on defense look at this He look like he got to get back door right now stop the only person on his team That's above average on the defensive side of the ball in the perimeter is Royce O'Neill and well they asked him to do a lot Anyway, Jalen Brunson gets the screen from maxi cleaver now You got to drop covers from a sound white side because all the centers and Utah Jazz system are As to just protect the paint right so what a maxi cleaver do he popped and then we got rotation We got open shot maxi cleaver. There's five seconds left on the clock here. Utah has the lead now Let me show you what happens Jalen Brunson. What does he do? He gets past Mike Conley with one dribble move and just like that He is one foot away from the paint on the gather step now What really go bear is assigned to do is to protect this little gold this this orange goal right here Don't let nobody get to that so what does he do he stops the dribble penetration and and a lot of the shots That maxi cleaver hit today were like completely uncontested But what you're about to see right now is that this is going to be a contest and really go bear Do you know why did he decided to contest this one? It's because there's no time for an offensive rebound He doesn't even trust his team to get to get a rebound when he's not there So now because he knows that no matter what is the last shot of the quarter I'm gonna get out there and try to get a contest. He still got mouthpiece but this is the time where he gets a contest because He hasn't have to worry about offensive rebound and if you just want to see like point poor effort It's the fourth quarter.  Hassan is trying to drop a little bit Look or look what Donovan Mitchell does right here Look at this contest. Ah That YMCA ask and test and this man had already hit six threes on the day How is this your contests when a man has hit six threes up to this point? I don't understand for the play even start Jalen bruntz has already passed Denuel house, right? Here we go little dribble penetration and again really go bear trying to protect the rim because a layup goes in 99% of the time drops down and it gives up to open look late rotation for Bogdanov it's open three That's that's the lead now. Okay, so this is the last maxically but made three if I'm not mistaken Look how easy Spencer then when he gets past Donovan Mitchell again. I'm not picking on Dono This is a whole perimeter defense thing for the Utah Jazz, right? Well in and out one two between He's at the rim. I don't care what you say he's passes defender He is one step away from the rim So we go bear again assigned to protect this thing because that layup is so very easy to hit he comes over and There it is the corner easy Bang, you know I'm saying it's it's just bad bad scheme and it's bad bad perimeter defense Nobody on this team can stay in front of their defender. Nobody. This is a frustrating game I couldn't imagine being a Utah Jazz fan right now I want this thing blown up as a as an outsider looking in they gotta do if you want to keep Donovan and Rudy Gobera for another season my Conley has to go. I'm sorry. I love my Conley I got a jersey shirt of my Conley shout out to Kobe for walking into the door Um, I got a jersey shirt of my Conley. He got to go at this point He's lost a step on the defensive side of the ball where he was so very good by Donovan same thing We had a series early in his career Where he was going toe-to-toe with LeBron and holding holding his own because it's LeBron It's tough to stop him defensively He was doing this thing all of that has to go because they don't have anybody that you could trust on a perimeter And because of that Rudy Gobera has these games of national tv Where if you're not really thinking about it just looks like he's getting killed and he's not playing him He's not playing the best of his career, but he's definitely not getting killed And I think it was a tweet from Kevin O'Connor that was like, can you imagine if Rudy Gobera had a defender like Mikhail Bridges on this team How how good of a defense that can be if he just had one other defender One other defender and this is from ESPN stats and info the MAVs made 17 Uncontested threes over the Utah Jazz the most by any team and in the last 10 post seasons Do you do I need to read that to you one once did you hear how many uncontested threes that were Legitimately ridiculous and it has to change if they want to do anything But more than likely we're probably going to see a grand explosion of the Utah Jazz if they lose this series Because you should not be at 100 percent or near near it and losing to the dallas mavericks Who don't have their all NBA first team player this team doesn't even have another all start Nobody else here got one all star vote not one of them and you lost to this On rudie gay the guy that you signed that was supposed to be your small ball center Where you needed to be or what part of your lineup. He's getting d&p's coaching decisions Change needs to happen. All right, let's go to the next game raptors versus 76ers another dominant performance from joel and bead he ended with 31 11 and then tobias harris has been really good through the first two games of the post season Which is a a crazy development because of toby's gonna be good and you still have a joel and bead Performances and you still have mexican cleaver playing solid Oh snap the team that people thought might lose in the first round That's a little bit more difficult if toby is just well above average What he has been in these last couple games and I've been seeing a lot of conversations about um The officiating this game I don't think there's ever going to be a perfectly officiated game And that is the reason why you never see me come onto this show and say ah X team lost because miss call here or x team lost because this team shot so many free The 76ers have joel and bead and james harden, bro. They're gonna get calls That's just the way it has been and you going into game two of the first round of the playoffs thinking that something would change It's kind of weird. It's um is it perf is the right system? Probably not is a perfect system definitely not but I can't say that. Ah, man The things should have should have been different in game two This is the way joel and bead display basketball for the last five years This is the way that james saw this play basketball for the last eight years They're gonna go out there and get files But this is the thing though the the free throw discrepancy was big it's 30 to 20 or 12 It's 30 to 12 Um do out the entire game most of those free throws for joel I think joel and bead shot 11 free throws in the first quarter and in that um the first quarter The toronto raptors were winning the toronto raptors were winning that first quarter Even with joel and bead doing his thing It was the rest of the quarters where freve and bleat went from killer and first quarter to the last three just being nothing or or like Gary trin jr. Trying to give it a go. I respect it But he shouldn't have been out there honestly And I really like this raptor's team because I think that they could do some some things But they're just extremely undersized and I thought this could have been a series And I think a lot of people thought this could be a series where them being undersized was more of a positive Because we've seen some really good big players struggle when you put a small defender on them Kevin aranta said hey, I hate when the small one. He don't say that the tougher Kevin aranta never say this guy clamped me up You know I'm saying but you'll say the the tougher defenders are the smaller ones They're getting underneath you the jew holidays of the world and even like yoke is just having a tough time And I put that a quotation marks because he's still having you know putting up points tough time against a guy Like drake my green is significantly different or smaller than them. So I think a lot of people thought that hey Pristatouya might foul a lot But we think he could give jolly beat a little bit of run, especially when you throw an ampask out Everyone's the way you're throwing at christmas shake has not been the case That's not been the case jolly beatus is dominant because he'll get you and foul trouble very very early on And that's part of the game plan. That's part of the way they do things You know it sucks that scotty barns couldn't play today But you know if there's any silver lining a ojana nobby in the playoffs is ridiculous You just like Again, when this is a team that wasn't even projected to be in the playoffs. So they're a five seed This is this has been a successful season for you even if it ends in four Um and the future's super bright But yeah, man, this wasn't just all free throws were or what won the 76ers game It was a lot deeper than that Oh And I say that deandre jordan has not played a single minute in this series deeper than that You know i'm saying uh, dr. Rivers is actually kind of coaching and for the second time in this series Um the 76ers won the jolly beat off the court minutes Those are the x factors in this series when joel and beat is off the floor You have to win if you want a chance of your toronto and I don't think they won that today So you lost and let's lastly talk about this warriors denver game because whoa um another Explosion for the the warriors the new def lineup hasn't played a ton of minutes together But it looks lethal. Um, stef curry is the best six man of all time. No disrespect to manu jenoble Stef curry comes in off his injury gate number one kind of mid gate number two 34 of them things Missed two free throws, which is weird to me. It was like penalty free throws too It was like tactical foul and off ball foul free throws. He missed both for those We got the jordan pool explosion being the real thing But that stef curry pulled thompson draemon wigs lineup Bro, they're gonna match up. So will across Uh potential very very deep playoff run, bro Very very deep playoff run the amount of confidence that jordan pool has is ridiculous And you would think with that def lineup that the defense wouldn't be great because at the at the helm of you Have stef curry and jordan pool But I've said this about like players like jj reddick who aren't necessarily good one-on-one defenders But if you have smart team defenders, you can hide those type of things And jordan pool has turned himself into a smart team defender Stef curry has has been a smart team defender, you know, I'm saying if you have good defenders around him And that's what wiggins and draemon green is and clay thompson is everything else can follow to play And it has they frustrated the hell out of different nuggets here We got fights on the sideline between will barton and the marcus cousins the frustration boiled over from the cole Yoko's the fact that he had to get ejected from this game Eric gordon has been a non-factor Offensively, these are the things that the warriors are doing to this different nuggets team now again the different I think it was even on the broadcast Vingundi jeff vingundi was saying out of all of the 16 teams that are in the playoffs the different nuggets has the least amount of firepower on offensive side of the ball Which is facts if yoko's is not creating it or yoko's is not doing it They don't score and you saw a lot of that today because they just they just couldn't do it And that warriors explosion you you should not be giving up for us at 44 points in a quarter that third quarter was Must watch television. So say out to the warriors, man. I don't know what else I could really say I I could do a 30 minute dive on jordan pool dive pool you give me that was not intentional Um, but I think everybody knows you know, it's always cool to me When a player goes from relatively obscure Which I would say jordan pool kind of was that last season And then he had the breakout if you want to call it that on uh the playing game And when I say obscure, I just mean that he wasn't a household name I think me and you knew who jordan pool was because we're diehard basketball fans But everybody didn't know the casual NBA fan probably didn't know the name jordan pool until last year's playing Where he was he was amazing, right and I always like to see a player go from Oh, he nice to oh bro is nasty. Oh, we expect him to drop 20 plus points a game now I always like to see that transition and now we're seeing that in like Desmond bain this season. We're seeing that in jordan pool this season We're seeing that in tiris maxi this season basically a lot of the most approved player candidates We're seeing them go from he could he got a spurts I could see the future being bright for him to the future might be now And now what is the future of this of his previous future? How good can jordan pool be realistically? I'm not I do not agree with this take, but there is discourse about jordan pool being the best player on the warriors I don't agree. I definitely don't agree. Don't hey, I'm telling you. I do not agree. I do not agree I do not agree But jordan pool is that good. He's not Steph Curry He's not even draymond green as far as overall impact on basketball because draymond green ended with a stat line of Six six three rebounds three steals in the block But I promise you he's one of the most impactful players in this game if you're watching But joining pool the fact that people even having that conversation. That's all I'm saying Uh, so yeah, man a good three slater games if you ask me a couple blowouts for show And that that nuggets war that knows the jazz maverick's game even though it made me mad Made up for the potential blowouts man tomorrow. We have hawk's heat Timberwolves grizzlies a jam around was live tweeting this Warriors game and you might I'm not listen. I'm not saying that you're gonna win the series But you might have to go against them boys next round. So you better be taking notes and then we got pale suns um Wow, I just realized that a lot of these eastern conference games are the day after But I mean it can be like the weekend and weekend We had basketball from like 12 to midnight the next day We can't do that because people have school and work shout out to the NBA That's the one thing the mlb does bro Bro, I woke up today and the red socks were playing against the tip. Was it the twins? I'm pretty sure it was the twins It was like 9 a.m. Why why are games starting that early? What are they doing every day? There's games starting at noon and one o'clock and like People we have a jobs bro. You know what I'm saying? I'm lucky that this is the job So I get to make the hours But bro, you cannot expect an accountant to watch your product if it's starting at one He's got clients coming in either way. Um, I'm excited about this this later games and uh talk to y'all tomorrow